Ochsner Cancer Institute | Strategic Alliance Partners

May 10, 2022

Jonathan Mizrahi, MD, discusses updates from the meeting in pancreatic cancer and hepatocellular carcinoma, the growing role of immunotherapy in GI cancer, and the ‘watch and wait’ protocol seen in rectal cancer

February 11, 2022

Laura Finn, MD, provides a deep dive into pivotal data with combinations and novel agents that have changed the paradigm for patients with newly diagnosed, early relapsed, and late relapsed multiple myeloma.

January 19, 2022

John Cole, MD, discusses the next steps with tucatinib in HER2-positive breast cancer.

January 17, 2022

Laura Finn, MD, discusses the utility of belantamab mafodotin-blmf in late relapsed multiple myeloma.

December 22, 2021

December 14, 2021

August 16, 2021

Data that emerged from the 2021 ASCO Annual Meeting represent potential paradigm shifts for patients with advanced melanoma.

September 29, 2020

The Gayle and Tom Benson Cancer Center at Ochsner Medical Center is celebrating its grand re-opening today after the completion of a $56 million expansion, which began in 2018.

February 21, 2020

If clinicians can identify complications earlier and take appropriate prophylactic or therapeutic measures, treatment plan adherence and outcomes may be improved for patients with head and neck cancer.

September 16, 2019

Ochsner Cancer Institute (Ochsner), along with its Gulf South NCI Community Oncology Research Program (NCORP) partners, has been awarded a $13.6 million grant by the National Cancer Institute to expand the successful statewide clinical trials network with a special emphasis on minority and underserved cancer patients.

August 23, 2019

The Gayle and Tom Benson Cancer Center at Ochsner Medical Center (Benson Cancer Center) has again been granted Three-Year Accreditation with Commendation from The Commission on Cancer, a quality program of the American College of Surgeons.